Last mentioned: Feb 24, 2026
Payer Agreement Shift
New payer contracts take effect, shifting GTN expectations to the high 30% range for the fiscal year.
Q4 Milestone
Patient count surpasses 36,000 and quarterly revenue exceeds $320 million.
Patent Extension
Secured Rezdiffra patent protection through 2045.
DGAT-2 and siRNA Expansion
Acquired late-stage DGAT-2 inhibitor and six preclinical siRNA assets.
GLP-1 Strategic Acquisition
Madrigal makes a $120 million upfront payment for an oral GLP-1 asset to expand its metabolic pipeline.
GLP-1 Acquisition
Madrigal paid $120 million upfront to acquire an oral GLP-1 program.
Rezdiffra Commercial Launch
First full year of Rezdiffra availability in the U.S. market for MASH.
Rezdiffra Full-Year Launch
Madrigal begins its first full year of commercial sales for the first-ever approved MASH treatment.
Madrigal Pharmaceuticals reported a transformative 2025, with Rezdiffra net sales reaching $958.4 million during its first full year on the market. The company is aggressively pivoting toward a multi-asset metabolic powerhouse, integrating oral GLP-1 and DGAT-2 programs alongside its core MASH franchise.
The Q4 2025 earnings cycle reveals a retail landscape defined by digital efficiency and premiumization, with Carvana and Freshpet posting double-digit volume growth. Companies are increasingly leveraging loyalty ecosystems and strategic partnerships to drive margins in a stabilizing consumer market.
Madrigal Pharmaceuticals reported a transformative Q4 2025, with Rezdiffra net sales reaching $321.1 million and a patient base exceeding 36,000. The company is aggressively expanding its metabolic pipeline, integrating GLP-1 and siRNA technologies to solidify its leadership in the MASH market.